6 results about "Injectable Lyophilized Powder" patented technology

This invention discloses a phosphorylated diamine morpholino oligonucleotide drug that regulates PAPOLA expression and its application, belonging to the field of biomedical technology. The nucleotide sequence of the drug is shown in SEQ ID NO:1, targeting the coding region of human PAPOLA mRNA. The formulation is a lyophilized powder for injection, with excipients including mannitol and phosphate buffer. This invention also discloses the application of this drug in the preparation of a treatment for gastric cancer, specifically advanced gastric cancer with high PAPOLA expression. The drug is administered intravenously at a dose of 8-12 mg / kg every 3 days. Its mechanism of action is to block PAPOLA protein translation, inhibit the G1 / S phase transition of gastric cancer cells, and induce apoptosis. In vitro and in vivo experiments have confirmed that this drug can specifically inhibit the proliferation and growth of gastric cancer cells, providing a new treatment option for advanced gastric cancer.

Provided is a novel recombinant human thrombopoietin composition. More specifically, provided is a composition, the composition comprising thrombopoietin (TPO), one or more protein protecting agents, a filler, a surfactant and a pH adjusting agent, and the composition being free of human serum albumin. Provided are a method for preparing a lyophilized powder for injection and a lyophilized powder for injection prepared by the method. The method comprises performing pre-freezing at about −50°C or below or about −45°C or below , performing primary drying at about −40°C to about 0°C, and performing secondary drying at about 0°C to about 30°C.

The invention relates to the technical field of biological medicine, in particular to amphotericin B liposome and a preparation method thereof.The preparation method comprises the steps that S1, amphotericin B, a film-forming material, an antioxidant and an acidified organic solvent are evenly mixed and dried to obtain fat powder; s2, the fat powder is subjected to hydration, homogenization, filtration, incubation and freeze drying in sequence; the incubation temperature is 60 to 70 DEG C, and the incubation time is 2 to 12 hours. The liposome prepared by the method provided by the invention is a round small single-chamber liposome with a uniform form; through detection, the amphotericin B lipid compound has the compounding rate of more than or equal to 99%, the particle size is small, the average particle size is less than or equal to 100nm, the particle size after redissolving is 50-150nm, the toxicity is low (the potassium release value is high), and the amphotericin B lipid compound can be prepared into low-toxicity freeze-dried powder injection for injection.

The application discloses a kind of 13 The application discloses a mefedrone injection lyophilized powder injection and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. 13 The mefedrone injection lyophilized powder injection is prepared by a freeze-drying method from raw materials, and the raw materials include 13 Mefedrone, excipients, cosolvents and pH regulators. 13 The raw drug mefedrone is prepared into 13 The mefedrone injection lyophilized powder injection is used, and the stability of the raw drug mefedrone is improved, and storage and transportation are facilitated. 13 The mefedrone injection lyophilized powder injection can be used for preparing drugs, reagents or kits for disease diagnosis, liver reserve function evaluation and preoperative and postoperative evaluation of liver surgery. 13 The mefedrone injection lyophilized powder injection can be used for preparing drugs, reagents or kits for disease diagnosis, liver reserve function evaluation and preoperative and postoperative evaluation of liver surgery.

This invention relates to a novel recombinant human thrombopoietin composition. More specifically, this invention relates to a composition comprising thrombopoietin (TPO), one or more protein protectants, fillers, surfactants, and pH adjusters, and the composition is free of human serum albumin. This invention also relates to a method for preparing a lyophilized powder for injection and the lyophilized powder for injection prepared by this method, the method comprising pre-freezing at a temperature below about -50°C or about -45°C, a first drying at a temperature from about -40°C to about 0°C, and a second drying at a temperature from about 0°C to about 30°C.

The present invention relates to the technical field of medicine and provides a preparation method for large-specification dihydroxyboronphenylalanine lyophilized powder for injection. The preparation method for large-specification dihydroxyboronphenylalanine lyophilized powder for injection includes: mixing dihydroxyboronphenylalanine, a polyol, a base, and part of a solvent to obtain a first mixed solution; adjusting the pH of the first mixed solution by using a pH regulator, and adding the remaining part of the solvent to obtain a second mixed solution, wherein the concentration of dihydroxyboronphenylalanine in the second mixed solution is 160-250 mg / mL; and aliquoting the second mixed solution, followed by lyophilization, where the lyophilization includes pre-freezing, sublimation drying, and desorption drying. By the preparation method of the present invention, stable large-specification dihydroxyboronphenylalanine lyophilized powder for injection can be prepared. The method of the present invention has the characteristics of stable process and reasonable lyophilization time, thereby greatly reducing the lyophilization costs.